Browse > Article
http://dx.doi.org/10.5483/BMBRep.2021.54.9.070

IRF2 enhances RANKL-induced osteoclast differentiation via regulating NF-κB/NFATc1 signaling  

Kim, Inyoung (Department of Pharmacology, Chonnam National University Medical School)
Kim, Jung Ha (Department of Pharmacology, Chonnam National University Medical School)
Kim, Kabsun (Department of Pharmacology, Chonnam National University Medical School)
Seong, Semun (Department of Pharmacology, Chonnam National University Medical School)
Lee, Keun-Bae (Department of Orthopedic Surgery, Chonnam National University Medical School and Hospital)
Kim, Nacksung (Department of Pharmacology, Chonnam National University Medical School)
Publication Information
BMB Reports / v.54, no.9, 2021 , pp. 482-487 More about this Journal
Abstract
Interferon regulatory factors (IRFs) play roles in various biological processes including cytokine signaling, cell growth regulation and hematopoietic development. Although it has been reported that several IRFs are involved in bone metabolism, the role of IRF2 in bone cells has not been elucidated. Here, we investigated the involvement of IRF2 in RANKL-induced osteoclast differentiation. IRF2 overexpression in osteoclast precursor cells enhanced osteoclast differentiation by regulating the expression of NFATc1, a master regulator of osteoclastogenesis. Conversely, IRF2 knockdown inhibited osteoclast differentiation and decreased the NFATc1 expression. Moreover, IRF2 increased the translocation of NF-κB subunit p65 to the nucleus in response to RANKL and subsequently induced the expression of NFATc1. IRF2 plays an important role in RANKL-induced osteoclast differentiation by regulating NF-κB/NFATc1 signaling pathway. Taken together, we demonstrated the molecular mechanism of IRF2 in osteoclast differentiation, and provide a molecular basis for potential therapeutic targets for the treatment of bone diseases characterized by excessive bone resorption.
Keywords
IRF2; NFATc1; NF-${\kappa}B$; Osteoclast;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kang IS and Kim C (2016) NADPH oxidase gp91(phox) contributes to RANKL-induced osteoclast differentiation by upregulating NFATc1. Sci Rep 6, 38014   DOI
2 Franzoso G, Carlson L, Xing L et al (1997) Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11, 3482-3496   DOI
3 Lee HI, Lee GR, Lee J et al (2020) Dehydrocostus lactone inhibits NFATc1 via regulation of IKK, JNK, and Nrf2, thereby attenuating osteoclastogenesis. BMB Rep 53, 218-222   DOI
4 Takatsuna H, Asagiri M, Kubota T et al (2005) Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res 20, 653-662   DOI
5 Abu-Amer Y (2013) NF-κB signaling and bone resorption. Osteoporos Int 24, 2377-2386   DOI
6 Kim I, Kim JH, Kim K, Seong S and Kim N (2017) Tusc2/Fus1 regulates osteoclast differentiation through NF-κB and NFATc1. BMB Rep 50, 454-459   DOI
7 Boyle WJ, Simonet WS and Lacey DL (2003) Osteoclast differentiation and activation. Nature 423, 337-342   DOI
8 Kim JH and Kim N (2014) Regulation of NFATc1 in osteoclast differentiation. J Bone Metab 21, 233-241   DOI
9 Kim JH and Kim N (2016) Signaling pathways in osteoclast differentiation. Chonnam Med J 52, 12-17   DOI
10 Asagiri M, Sato K, Usami T et al (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202, 1261-1269   DOI
11 Takayanagi H, Kim S, Koga T et al (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3, 889-901   DOI
12 Solt LA and May MJ (2008) The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res 42, 3-18   DOI
13 Hayden MS and Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18, 2195-2224   DOI
14 Novack DV, Yin L, Hagen-Stapleton A et al (2003) The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 198, 771-781   DOI
15 Iotsova V, Caamano J, Loy J, Yang Y, Lewin A and Bravo R (1997) Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3, 1285-1289   DOI
16 Boyce BF, Xiu Y, Li J, Xing L and Yao Z (2015) NF-κB-mediated regulation of osteoclastogenesis. Endocrinol Metab (Seoul) 30, 35-44   DOI
17 Vaira S, Johnson T, Hirbe AC et al (2008) RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci U S A 105, 3897-3902   DOI
18 Yanai H, Negishi H and Taniguchi T (2012) The IRF family of transcription factors: inception, impact and implications in oncogenesis. Oncoimmunology 1, 1376-1386   DOI
19 Masumi A, Fukazawa H, Shimazu T et al (2006) Nucleolin is involved in interferon regulatory factor-2-dependent transcriptional activation. Oncogene 25, 5113-5124   DOI
20 Masumi A, Yamakawa Y, Fukazawa H, Ozato K and Komuro K (2003) Interferon regulatory factor-2 regulates cell growth through its acetylation. J Biol Chem 278, 25401-25407   DOI
21 Luo W and Skalnik DG (1996) Interferon regulatory factor-2 directs transcription from the gp91phox promoter. J Biol Chem 271, 23445-23451   DOI
22 Jesse TL, LaChance R, Iademarco MF and Dean DC (1998) Interferon regulatory factor-2 is a transcriptional activator in muscle where It regulates expression of vascular cell adhesion molecule-1. J Cell Biol 140, 1265-1276   DOI
23 Zhao B, Takami M, Yamada A et al (2009) Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med 15, 1066-1071   DOI
24 Nakashima Y and Haneji T (2013) Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss. PLoS One 8, e72033   DOI
25 Salem S, Gao C, Li A et al (2014) A novel role for interferon regulatory factor 1 (IRF1) in regulation of bone metabolism. J Cell Mol Med 18, 1588-1598   DOI
26 Muhammad K, Alrefai H, Marienfeld R et al (2014) NF-κB factors control the induction of NFATc1 in B lymphocytes. Eur J Immunol 44, 3392-3402   DOI
27 Kim I, Kim JH, Kim K, Seong S and Kim N (2019) The IRF2BP2-KLF2 axis regulates osteoclast and osteoblast differentiation. BMB Rep 52, 469-474   DOI
28 Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289, 1504-1508   DOI
29 Zhao GN, Jiang DS and Li H (2015) Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. Biochim Biophys Acta 1852, 365-378   DOI
30 Ge X, Jin Q, Zhang F, Yan T and Zhai Q (2009) PCAF acetylates {beta}-catenin and improves its stability. Mol Biol Cell 20, 419-427   DOI
31 Ihn HJ, Kim TH, Kim K et al (2019) 2-O-digalloyl-1,3,4,6-tetra-O-galloyl-βκ-D-glucose isolated from Galla Rhois suppresses osteoclast differentiation and function by inhibiting NF-κB signaling. BMB Rep 52, 409-414   DOI
32 Alsamman K and El-Masry OS (2018) Interferon regulatory factor 1 inactivation in human cancer. Biosci Rep 38, 1-14
33 Chae M, Kim K, Park SM et al (2008) IRF-2 regulates NF-kappaB activity by modulating the subcellular localization of NF-kappaB. Biochem Biophys Res Commun 370, 519-524   DOI